- Home
- IMMX vs CLSD Comparison
IMMX vs CLSD Comparison
Compare IMMX & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- CLSD
- Stock Information
- Founded
- IMMX 2014
- CLSD 2011
- Country
- IMMX United States
- CLSD United States
- Employees
- IMMX N/A
- CLSD N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- CLSD Health Care
- Exchange
- IMMX Nasdaq
- CLSD Nasdaq
- Market Cap
- IMMX 61.1M
- CLSD 68.4M
- IPO Year
- IMMX 2021
- CLSD 2016
- Fundamental
- Price
- IMMX $2.65
- CLSD $0.38
- Analyst Decision
- IMMX Strong Buy
- CLSD Hold
- Analyst Count
- IMMX 1
- CLSD 4
- Target Price
- IMMX $7.00
- CLSD $4.33
- AVG Volume (30 Days)
- IMMX 220.7K
- CLSD 13.1M
- Earning Date
- IMMX 08-11-2025
- CLSD 08-11-2025
- Dividend Yield
- IMMX N/A
- CLSD N/A
- EPS Growth
- IMMX N/A
- CLSD N/A
- EPS
- IMMX N/A
- CLSD N/A
- Revenue
- IMMX N/A
- CLSD $3,764,000.00
- Revenue This Year
- IMMX N/A
- CLSD $78.37
- Revenue Next Year
- IMMX N/A
- CLSD $17.79
- P/E Ratio
- IMMX N/A
- CLSD N/A
- Revenue Growth
- IMMX N/A
- CLSD N/A
- 52 Week Low
- IMMX $1.26
- CLSD $0.29
- 52 Week High
- IMMX $3.20
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- IMMX 49.64
- CLSD 32.77
- Support Level
- IMMX $2.63
- CLSD $0.43
- Resistance Level
- IMMX $3.20
- CLSD $0.57
- Average True Range (ATR)
- IMMX 0.22
- CLSD 0.12
- MACD
- IMMX -0.04
- CLSD -0.02
- Stochastic Oscillator
- IMMX 3.51
- CLSD 15.93
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.